Article

TASP1-mediated cleavage of REV3L enhances the activity of DNA polymerase ζ in mammalian cells

The Kannouche team contributed to this study, published in Cancer Cell (2026), reporting the results of the ICARUS-LUNG01 Phase II trial: Efficacy, Safety, and Biomarker Analysis of Datopotamab Deruxtecan in Advanced Non-Small Cell Lung Cancer. The study evaluates the clinical activity, safety profile, and predictive biomarkers associated with datopotamab deruxtecan in patients with advanced non-small cell lung cancer.

Read More

Efficacy, safety, and biomarker analysis of datopotamab deruxtecan in advanced non-small cell lung cancer: ICARUS-LUNG01 phase 2 study

The Kannouche team contributed to this study, published in Cancer Cell (2026), reporting the results of the ICARUS-LUNG01 Phase II trial: Efficacy, Safety, and Biomarker Analysis of Datopotamab Deruxtecan in Advanced Non-Small Cell Lung Cancer. The study evaluates the clinical activity, safety profile, and predictive biomarkers associated with datopotamab deruxtecan in patients with advanced non-small cell lung cancer.

Read More

Changes in the architecture and abundance of replication intermediates at UV-stalled replication forks in human cells

This is a collaborative effort of the Kannouche and Mazon/LeCam teams of the unit. DNA lesions during S phase challenge genome stability, managed by DNA damage tolerance (DDT) via TLS polymerases or recombination. Using electron microscopy, we show TLS polymerase η acts at replication forks to prevent gaps after UV damage. We outline a timeline of UV damage tolerance highlighting polη’s crucial role in DNA synthesis continuity.

Read More